Date: 2015-06-22
Type of information: R&D agreement
Compound: CTX-derived exosomes
Company: ReNeuron (UK) Benitec Pharma (Australia)
Therapeutic area: Cancer - Oncology
Type agreement: R&D
Action mechanism: gene therapy/cell therapy. Exosomes are nanoparticles secreted from all cells and which are believed to play a key role in the transfer of beneficial proteins and particularly non-coding RNAs from one cell to another. ReNeuron aims to exploit the therapeutic potential of exosomes derived from its own proprietary stem cell lines. CTX-derived exosomes may become a valuable new pipeline of cancer therapeutic candidates. We are also delighted to be extending our research collaboration with Benitec to explore the potential of our exosomes as a delivery system for Benitec\'s unique gene silencing technology targeting drug resistant cancers.\"
Disease: lung cancer and other drug resistant cancers
Details: * On June 22, 2015, ReNeuron, a leading UK-based stem cell therapy company, announced the extension of an ongoing research collaboration with Australia-based Benitec Biopharma following positive results in early studies. Researchers at ReNeuron and Benitec, a leader in the field of therapeutics focused on gene silencing, have discovered that ReNeuron\'s CTX-derived exosomes are potentially an effective delivery system for Benitec\'s proprietary ddRNAi gene silencing technology, resulting in the silencing of specific genes in recipient cells to beneficial therapeutic effect. These early studies also indicate that ReNeuron\'s CTX stem cells are a more effective producer cell type for this purpose than mesenchymal cells, a widely used cell type against disease targets in stem cell therapy. Following these exploratory studies, ReNeuron is extending its research collaboration with Benitec in order to further test the potential of this combination technology approach, targeting lung cancer and other drug resistant cancers.
Financial terms:
Latest news:
